Business Law and Corporate Law

Subscribe
Business law and corporate law thought leadership, articles, podcasts, videos and webinars from expert sources across the legal world. Explore insights covering topics that involve business and corporate law produced by specialists working in this area every day.
Article
《信披办法》视角下私募基金管理人违规披露、不披露重要信息罪的适用边界——私募基金合规与风险防范实务探究系列①
近年来,随着私募基金行业的快速发展,“强监管、防风险”已成为行业主旋律,穿透式监管态势日益趋严。在募、投、管、退的全生命周期中,如何坚守合规底线?当管理人触碰刑事红线时,法律定性边界何在?而在风险爆发后,投资者又该如何在民刑交叉的复杂局面中寻找最优维权路径ᦃ
China Commercial
AB
AnJie Broad Law Firm
Article
《最高人民法院关于审理建设工程施工合同纠纷案件适用法律问题的解释(二)》新旧条文对比分析
China's Supreme People's Court has issued a comprehensive new judicial interpretation for construction contract disputes, effective June 30, 2026. This interpretation fundamentally reshapes key areas including contractor payment rights, quality assurance mechanisms, and priority claim procedures. The new rules significantly restrict direct claims by subcontractors against project owners while strengthening protections for legitimate contractors and migrant workers.
China Commercial
JT
Beijing Jincheng Tongda & Neal Law Firm
Article
董责险与我国资本市场主要监管体系概述及保险公司实务应对要点(上篇)——董责险与资本市场监管体系概览
董责险的全称为“董事、监事及高级管理人员责任保险”,英文为Directors & Officers Liability Insurance,通常简称为D&O保险,是以董事、监事、高级管理人员(“董监高”)在执行职务过程中的不当行为造成第三方损害而应承担的赔偿责任为保险标的。
China Commercial
AB
AnJie Broad Law Firm
See more
Article
董责险与我国资本市场主要监管体系概述及保险公司实务应对要点(下篇) ——保险公司承保与理赔阶段的实务应对要点
上篇梳理了董责险与我国资本市场监管体系之间的制度脉络,从证监会的行政处罚、行政监管措施,到证券交易所层面的自律监管与纪律处分。然而对保险公司而言,真正的挑战在于如何将上述监管规则的变化转化为具体的承保评估标准与理赔应对策略。
China Insurance
AB
AnJie Broad Law Firm
See more
Article
Connecting The Dots: China’s Evolving Standard For Numerical Sub-Range Amendments
China's patent authority has issued a landmark decision clarifying how numerical ranges and subsequently added experimental data are evaluated when claiming priority in pharmaceutical patents. The ruling establishes that while new efficacy data can support priority claims for explicitly disclosed ratios, numerical values that merely fall within a disclosed range—but were never specifically mentioned—constitute new subject matter and lose priority protection.
China IP
EI
Eagle IP
See more
Article
Connecting The Dots: China’s Evolving Standard For Numerical Sub-Range Amendments
China's patent authority has issued a landmark decision clarifying how numerical ranges and subsequently added experimental data are evaluated when claiming priority in pharmaceutical patents. The ruling establishes that while new efficacy data can support priority claims for explicitly disclosed ratios, numerical values that merely fall within a disclosed range—but were never specifically mentioned—constitute new subject matter and lose priority protection.
China IP
EI
Eagle IP
See more